Gabexate (Foy)

A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Also Known As:

Foy; Gabexate Mesilate; Gabexate Mesylate; Gabexate Methanesulfonate; Gabexate Monomethanesulfonate; Gabexate Monomethanesulfonate, 14C-Labeled Cpd; Gabexate Monomethanesulfonate, 14C Labeled Cpd; Mesilate, Gabexate; Mesylate, Gabexate; Methanesulfonate, Gabexate; Monomethanesulfonate, Gabexate; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester

Networked: 285 relevant articles (71 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amidines: 14
  - Guanidines: 29
    - Gabexate: 285

Experts

1.	Ranieri, Girolamo: 5 articles (01/2021 - 01/2013)
2.	Ammendola, Michele: 4 articles (01/2021 - 01/2013)
3.	Andriulli, Angelo: 4 articles (04/2007 - 10/2002)
4.	Song, Qing: 3 articles (04/2022 - 10/2015)
5.	Gadaleta, Cosmo Damiano: 3 articles (01/2021 - 01/2014)
6.	Sacco, Rosario: 3 articles (10/2015 - 01/2013)
7.	Sammarco, Giuseppe: 3 articles (10/2015 - 01/2013)
8.	Leandro, Gioacchino: 3 articles (04/2007 - 10/2002)
9.	Pezzilli, Raffaele: 3 articles (05/2006 - 05/2003)
10.	Mariani, Alberto: 3 articles (10/2003 - 04/2002)

Related Diseases

1.	Pancreatitis 03/01/2003 - "Gabexate mesilate has been proven effective in the treatment of severe acute pancreatitis with organ dysfunction. " 07/01/2000 - "There are strong indications from this study that early intravenous gabexate mesilate infusion results in improved survival in acute pancreatitis with organ dysfunctions." 07/09/2007 - "Long-term (12 hours) infusion of gabexate significantly decreased the incidence of post-ERCP pancreatitis; however, no prophylactic effect was observed for short-term infusion (2.5 and 6.5 hours). " 08/01/2006 - "Routine gabexate prophylaxis was associated with a significant reduction of post-ERCP pancreatitis rate, severe hyperamylasaemia and hospitalisation-related costs only in high-risk patients. " 06/01/2006 - "The administration of gabexate mesilate has been reported to be effective for the prevention for post-ERCP pancreatitis when given during and after the procedure. "
2.	Disseminated Intravascular Coagulation 11/01/1993 - "Treatment of disseminated intravascular coagulation with gabexate mesilate." 01/01/1983 - "Protective effect of gabexate mesilate against experimental disseminated intravascular coagulation in rats." 06/01/1988 - "Gabexate as a therapy for disseminated intravascular coagulation." 09/01/2004 - "Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery." 01/01/2005 - "Gabexate Mesilate was also added for disseminated intravascular coagulation syndrome probably associated with rhabdomyolysis. "
3.	Hemorrhage 09/01/2003 - "Continuous infusion of gabexate mesilate proved effective for improvement of systemic bleeding tendency. " 05/01/1986 - "FOY is an effective agent and may decrease postdialysis bleeding complications in certain high-risk patients." 08/01/2006 - "Beneficial effect of gabexate mesilate on microscopic polyangiitis with renal dysfunction and pulmonary hemorrhage: A case report." 11/01/2000 - "The combined use of heparin and gabexate mesilate was considered to be very effective for improving this condition, although a slight increase in rectal bleeding was recognized for a short time." 01/01/1996 - "The profound actions of aprotinin, FUTHAN, and FOY to inhibit bleeding and prevent the need for donor blood are well known. "
4.	Infections 09/01/2004 - "Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery." 04/01/1990 - "On the basis of this study the hypothesis is not confirmed that treatment with gabexate mesilate for necrotizing experimental pancreatitis with additional gram-negative infection has a therapeutic efficiency." 09/01/1994 - "This characteristic of gabexate mesilate may facilitate protection against infecting micro-organisms, although the inhibition of reactive oxygen species production by neutrophils may be a disadvantage for host-defense against infection." 04/01/1990 - "[The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis]." 09/01/2012 - "Antithrombin may be a more effective treatment for coagulation and fibrinolysis disorders than gabexate mesilate in infection-related DIC, but there was no difference in 28-day mortality."
5.	Shock 01/01/2023 - "Enteral gabexate mesilate was able to maintain vascular function in experimental T/HS, which was reflected by improved hemodynamics (mean arterial pressure 50.39 ± 7.91 vs. 64.95 ± 3.43 mmHg, Shock-control vs. GM treated, p = 0.0001). " 05/01/1990 - "In 1987, Foy et al. reported that hippocampal LTP was impaired by exposure to inescapable shock. " 01/01/1983 - "Effects of gabexate mesilate on the reactions of lipid metabolism in endotoxic shock." 05/01/1993 - "Evaluation of seriousness of shock on beginning of therapy and during the follow-up period was performed on the basis of the same "shock score" (Ogawa and Fujita, Jap J Surg 12:122, 1982) that was used in Japanese clinical studies on FOY in shock. " 09/01/2000 - "She recovered promptly with PCG, gabexate mesilate and intensive care for shock. "

Related Drugs and Biologics

1.	Gabexate (Foy)
2.	Protease Inhibitors (Protease Inhibitor)
3.	Somatostatin (Somatotropin Release-Inhibiting Factor)
4.	Dacarbazine (DIC)
5.	Heparin (Liquaemin)
6.	nafamostat
7.	Ceruletide
8.	urinastatin (MR 20)
9.	Peptide Hydrolases (Proteases)
10.	camostat

Related Therapies and Procedures

1.	Therapeutics
2.	Intra-Arterial Infusions
3.	Warm Ischemia
4.	Renal Dialysis (Hemodialysis)
5.	Transplantation